High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?

Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV

(2021) Jake A. Ruddy et al.   AIDS

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

(2021) Bezawit A Woldemeskel et al.   CLINICAL INFECTIOUS DISEASES

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

(2021) Itzchak Levy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

(2021) Peter Bergman et al.   EBioMedicine

Standard vaccines increase HIV-1 transcription during antiretroviral therapy

(2016) Christina Yek et al.   AIDS